Antivirogram: Marketed

Vircolab and partner Glaxo Wellcome plc (GLX; LSE:GLXO, London, U.K.) presented interim data from 218 patients in an ongoing 274-patient U.S. open-label study showing that changing HIV therapy based on phenotypic testing produced a greater reduction in viral load than standard care. After 16 weeks, patients in the phenotypic testing arm had a 0.93 log reduction in viral load and 58 percent HIV RNA <400 copies/mL, compared to a 0.6 log reduction and 37 percent of patients with viral loads <400 copies/mL with standard care. CD4 T cell counts were similar in the two groups. ...